Welcome to LookChem.com Sign In|Join Free

CAS

  • or

204915-50-4

Post Buying Request

204915-50-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

204915-50-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 204915-50-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,4,9,1 and 5 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 204915-50:
(8*2)+(7*0)+(6*4)+(5*9)+(4*1)+(3*5)+(2*5)+(1*0)=114
114 % 10 = 4
So 204915-50-4 is a valid CAS Registry Number.

204915-50-4Downstream Products

204915-50-4Relevant articles and documents

Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates

Jeffrey, Scott C.,Torgov, Michael Y.,Andreyka, Jamie B.,Boddington, Laura,Cerveny, Charles G.,Denny, William A.,Gordon, Kristine A.,Gustin, Darin,Haugen, Jennifer,Kline, Toni,Nguyen, ? Minh T.,Senter, Peter D.

, p. 1344 - 1358 (2007/10/03)

Antibody-drug conjugates (ADCs) were prepared consisting of DNA minor groove binder drugs (MGBs) attached to monoclonal antibodies (mAbs) through peptide linkers designed to release drugs inside the lysosomes of target cells. The site of linker attachment on the MGB was at the 5-position on the B-ring, since model studies showed that attachment of an electron-withdrawing group (i.e., acyl, carbamoyl) at this position increased the stability of the molecule. Because of the hydrophobic nature of the MGBs, several measures were required to overcome their tendencies to induce mAb aggregation upon conjugation. This is exemplified in the series of ADCs containing the amino-CBI drug 1. Initial adducts were prepared using the peptide sequence valine-citrulline, attached to a self-immolative para-aminobenzyl carbamate spacer. The resulting ADCs were completely aggregated. Removal of the self-immolative spacer, introduction of a more hydrophilic valine-lysine sequence, and incorporation of a tetraethyl-eneglycol unit between the mAb and the peptide resulted in conjugates that were nonaggregated, even with as many as eight drugs per mAb. These results were extended to include the hydroxy aza-CBI drug 2, which was linked to the valine-lysine sequence through a para-aminobenzyl ether self-immolative spacer. The resulting mAb conjugates were monomeric and released the hydroxy aza-CBI drug upon treatment with human cathepsin B. In vitro cytotoxicity assays established that the mAb-MGB drug conjugates were highly cytotoxic and effected immunologically specific cell kill at subsaturating doses. The results provide a general strategy for MGB prodrug design and illustrate the importance of linker hydrophilicity in making nonaggregated, active mAb-MGB conjugates.

A new short synthesis of 3-substituted 5-Amino-1-(chloromethyl)-1,2-dihydro-3H-benzo[e]indoles (Amino-CBIs)

Yang, Shangjin,Denny, William A.

, p. 8958 - 8961 (2007/10/03)

A new short synthesis of 3-substituted 5-amino-1-(chloromethyl)-1,2-dihydro-3H-benzo[e]indoles from Martius Yellow is disclosed. The key steps of the synthesis were three efficient regioselective reactions (iodination, 5-exo-trig aryl radical-alkene cyclization and carboxylation).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 204915-50-4